Daiichi Sankyo and Forest Laboratories sign agreement for Azor

PARSIPPANY, N.J. Daiichi Sankyo and Forest Labs have signed a contract for a co-promotional agreement in the United States for the drug Azor. The companies had first announced the agreement on Aug. 21, 2007.

Azor is a combination of two antihypertensives, amlodipine and olmesartan medoxomil. Daiichi Sankyo received approval from the Food and Drug Administration to market the drug on Sept. 26, 2007.

Forest will make an upfront payment of $20 million to Daiichi, which will be made in this quarter.